HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine.

Abstract
Excitotoxicity and oxidative stress mediate neuronal death after hypoxic-ischemic brain injury. We examined the possibility that targeting both N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity and oxidative stress would result in enhanced neuroprotection against hypoxic-ischemia. 2-Hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid (Neu2000) was derived from aspirin and sulfasalazine to prevent both NMDA neurotoxicity and oxidative stress. In cortical cell cultures, Neu2000 was shown to be an uncompetitive NMDA receptor antagonist and completely blocked free radical toxicity at doses as low as 0.3 micromol/L. Neu2000 showed marked neuroprotection in a masked fashion using histology and behavioral testing in two rodent models of focal cerebral ischemia without causing neurotoxic side effects. Neu2000 protected against the effects of middle cerebral artery occlusion, even when delivered 8 h after reperfusion. Single bolus administration of the drug prevented gray and white matter degeneration and spared neurologic function for over 28 days after MACO. Neu2000 may be a novel therapy for combating both NMDA receptor-mediated excitotoxicity and oxidative stress, the two major routes of neuronal death in ischemia, offering profound neuroprotection and an extended therapeutic window.
AuthorsByoung Joo Gwag, Young Ae Lee, Sun Young Ko, Moon Jung Lee, Doo Soon Im, Bok Sun Yun, Hyang Ran Lim, Sun Mi Park, Han Yeol Byun, Sun Ju Son, Hye Jin Kwon, Ji Yoon Lee, Jae-Young Cho, Seok Joon Won, Kee-Won Kim, Young Min Ahn, Ho Sang Moon, Hae Un Lee, Sung Hwa Yoon, Ji-Hyun Noh, Jun-Mo Chung, Sung Ig Cho
JournalJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (J Cereb Blood Flow Metab) Vol. 27 Issue 6 Pg. 1142-51 (Jun 2007) ISSN: 0271-678X [Print] United States
PMID17106444 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoic acid
  • Antioxidants
  • Benzoates
  • Excitatory Amino Acid Antagonists
  • Fluorobenzenes
  • Receptors, N-Methyl-D-Aspartate
  • Salicylates
  • meta-Aminobenzoates
  • Sulfasalazine
  • N-Methylaspartate
  • Aspirin
Topics
  • Animals
  • Antioxidants (pharmacology)
  • Aspirin (chemistry)
  • Benzoates (pharmacology, therapeutic use)
  • Brain Ischemia (drug therapy, prevention & control)
  • Cells, Cultured
  • Excitatory Amino Acid Antagonists (chemistry, pharmacology)
  • Fluorobenzenes
  • Infarction, Middle Cerebral Artery
  • Mice
  • N-Methylaspartate (antagonists & inhibitors)
  • Oxidative Stress (drug effects)
  • Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)
  • Salicylates
  • Sulfasalazine (chemistry)
  • meta-Aminobenzoates

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: